Company leads 2022 with major acquisition to expand position in the cardiology market
February 2022 saw Boston Scientific Corporation (Boston Scientific) complete the purchase of Baylis Medical Company Inc., a developer and manufacturer of advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. The purchase, completed at a cost of $1.75 billion, will allow Boston Scientific to integrate the Baylis platforms with its electrophysiology and structural heart offerings, strengthening its position within the highest growth cardiology markets. However, Baylis’ affiliate Baylis Medical Technologies was not included in the transaction and will remain a separate entity.
New Activity|M&AIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.